Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Wang, Xiaoying ^a   He, Xiangfeng ^a,b   Zhao, Fengshu ^a   Wang, Jing ^a   Zhang, Hongyi ^a   Shi, Fangfang ^a   Zhang, Yunxia ^a   Cai, Kai ^a   Dou, Jun ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Interleukin 21; Melanoma; miR200c; Tumor vaccine; Zinc finger E box binding homeobox 1

Indexed keywords

B16F10 CELL VACCINE; B16F10/GPI IL 21; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; INTERLEUKIN 21; INTERLEUKIN 4; LENTIVIRUS VECTOR; MICRORNA 200C; MITOXANTRONE; NERVE CELL ADHESION MOLECULE; RECOMBINANT RNA; RECOMBINANT VACCINE; SHORT HAIRPIN RNA; SMAD7 PROTEIN; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CANCER INHIBITION; CANCER TISSUE; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; LUNG METASTASIS; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SPLEEN CELL;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLYCOSYLPHOSPHATIDYLINOSITOLS; HOMEODOMAIN PROTEINS; IMMUNIZATION; INTERLEUKINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICRORNAS; NEOPLASM METASTASIS; SKIN NEOPLASMS; SPLEEN; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 84899147468     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-68     Document Type: Article

References (37)

1. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Morrison SJ. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523. 10.1016/j.ccr.2010.10.012, 3031091, 21075313.
2. Romano S, Staibano S, Greco A, Brunetti A, Nappo G, llardi G, Martinelli R, Sorrentino A, Di Pace A, Mascolo M, Bisogni R, Scalvenzi M, Alfano B, Romano MF. FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential. Cell Death Dis 2013, 4:e578. 10.1038/cddis.2013.109, 3641332, 23559012.
3. Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, Costantini M, Scarpi E, Amadori D, Ridolfi R. Ipilimumab in advanced melanoma: reports of long-lasting responses. Melanoma Res 2012, 22:263-270. 10.1097/CMR.0b013e328353e65c, 22516968.
4. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014, 11:24-37.
5. Kwek SS, Cha E, Fong L. Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer 2012, 12:289-297. 10.1038/nrc3223, 3433280, 22378189.
6. Naghibalhossaini F, Yoder AD, Tobi M, Stammers CP. Evolution of a tumorigenic property conferred by glycophosphatidyl-inositolmembrane anchors of carcinoembryonic antigen gene family members during the primate radiation. Mol Biol Cell 2007, 18:1366-1374. 10.1091/mbc.E06-10-0884, 1838992, 17287394.
7. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009, 15:2123-2129. 10.1158/1078-0432.CCR-08-2663, 19276257.
8. Davis JM, Harris MP, Davidson NE, Kobrin BJ, Jaffee EM, Emens LA. Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. Cytotherapy 2005, 7:46-56. 10.1016/S1465-3249(05)70788-X, 16040383.
9. Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev 2006, 25:233-242. 10.1007/s10555-006-8503-7, 16770535.
10. Zhao F, Dou J, Wang J, Chu L, Tang Q, Wang Y, Li Y, Cao M, Hu W, Hu K, Feng He X, Gu N. Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice. Immunobiology 2010, 215:89-100. 10.1016/j.imbio.2009.02.003, 19457579.
11. Zhao F, Dou J, He XF, Wang J, Chu L, Hu W, Yu F, Hu K, Wu Y, Gu N. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model. Vaccine 2010, 28:2846-2852. 10.1016/j.vaccine.2010.01.057, 20153795.
12. Ulrike B, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9:582-589. 10.1038/embor.2008.74, 2396950, 18483486.
13. Bracken CP, Gregory PA, Kolesnikoff N. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial- mesenchymal transition. Cancer Res 2008, 68:7846-7854. 10.1158/0008-5472.CAN-08-1942, 18829540.
14. Chen D, Wang J, Zhang Y, Chen J, Yang C, Cao W, Zhang H, Liu Y, Dou J. Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells. Int J Gynecol Cancer 2013, 23:1357-1366. 10.1097/IGC.0b013e3182a5e760, 24257549.
15. Chen D, Zhang Y, Wang J, Chen J, Yang C, Cai K, Wang X, Shi F, Dou J. MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res 2013, 6:50. 10.1186/1757-2215-6-50, 3729499, 23842108.
16. He X, Wang J, Zhao F, Yu F, Chen D, Cai K, Yang C, Chen J, Dou J. Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse. Immune Res 2012, 53:240-249.
17. Bendoraite A, Knouf EC, Garg KS. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010, 116:117-125. 10.1016/j.ygyno.2009.08.009, 2867670, 19854497.
18. Dou J, He XF, Cao WH, Zhao FS, Wang XY, Liu YR, Wang J. Overexpression of microRNA-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice. Cell Mol Biol 2013, 59:OL1861-OL1868.
19. Wang J, Zhou DD, He XF, Wang Y, Hu W, Jiang L, Dou J. Effect of downregulated β-catenin on cell proliferative activity, the sensitivity to chemotherapy drugs and tumorigenicity of ovarian cancer cells. Cell Mol Biol 2011, 57:OL1606-OL1613.
20. Zhang H, Wang J, Cai K, Jiang L, Zhou D, Yang C, Chen J, Chen D, Dou J. Downregulation of gene MDR1 by shRNA to reverse multidrug- resistance of ovarian cancer A2780 cells. J Cancer Res Ther 2012, 8:226-231. 10.4103/0973-1482.98975, 22842366.
21. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther 2012, 11:2556-2565. 10.1158/1535-7163.MCT-12-0463, 3519949, 23074172.
22. Liu SJ, Tetzlaff MT, Cui R, Xu X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1. Am J Pathol 2012, 181:1823-1835. 10.1016/j.ajpath.2012.07.009, 3483804, 22982443.
23. Rosenberg SA, Sherry RM, Morton KE. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005, 175:6169-6176.
24. Dou J, Wu Y, Wang J, Zhao F, Chu L, Liu C, Wen P, Hu W, Hu K, He XF, Gu N. Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21. Cancer Gene Ther 2010, 17:675-683. 10.1038/cgt.2010.23, 20539320.
25. Hervé L, Michèle F, Sylvie G. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 2001, 253:177-187. 10.1016/S0022-1759(01)00359-3, 11384679.
26. Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, Lassus H, Wang L, Katsaros D, Montone K, Zhao X, Zhang Y, Butzow R, Coukos G, Zhang L. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer 2010, 70:9463-9472.
27. Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010, 8:27. 10.1186/1479-5876-8-27, 2855523, 20302635.
28. Bierie B, Moses HL. Tumour microenvironment: TGF beta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506-520. 10.1038/nrc1926, 16794634.
29. Massague' J. TGF in cancer. Cell 2008, 134:215-230. 10.1016/j.cell.2008.07.001, 3512574, 18662538.
30. Qu X, Shen L, Zheng Y, Cui Y, Feng Z, Liu F, Liu J. A signal transduction pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its correlation with progression in human melanoma. J Invest Dermatol 2014, 134:159-167. 10.1038/jid.2013.281, 23792459.
31. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890. 10.1016/j.cell.2009.11.007, 19945376.
32. Liu S, Tetzlaff MT, Liu A, Liegl-Atzwanger B, Guo J, Xu X. Loss of microRNA-205 expression is associated with melanoma progression. Lab Invest 2012, 92:1084-1096. 10.1038/labinvest.2012.62, 22525428.
33. Ulloa L, Doody J, Massagué J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999, 397:710-713. 10.1038/17826, 10067896.
34. Hirano T, Satow R, Kato A, Tamura M, Murayama Y, Saya H, Kojima H, Nagano T, Okabe T, Fukami K. Identification of novel small compounds that restore E-cadherin expression and inhibit tumor cell motility and invasiveness. Biochem Pharmacol 2013, 86:1419-1429. 10.1016/j.bcp.2013.09.001, 24035834.
35. Wen FQ, Liu X, Kobayashi T, Abe S, Fang Q, Kohyama T, Ertl R, Terasaki Y, Manouilova L, Rennard SI. Interferon-gamma inhibits transforming growth factor-beta production in human airway epithelial cells by targeting Smads. Am J Respir Cell Mol Biol 2004, 30:816-822. 10.1165/rcmb.2002-0249OC, 14722222.
36. Weng H, Mertens PR, Gressner AM, Dooley S. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 2007, 46:295-303.
37. Kuga H, Morisaki T, Nakamura K, Onishi H, Noshiro H, Uchiyama A, Tanaka M, Katano M. Interferon-gamma suppresses transforming growth factor-beta-induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model. Oncogene 2003, 22:7838-7847. 10.1038/sj.onc.1207046, 14586410.